Cases of EGFRM+ NSCLC with poor response to EGFR-TKIs due to pre-treatment co-mutations in other cancer-drivers have been documented by several groups [12,17,38,44,51,52,68,116,117,118,124,139,140,141]. The gene discussed is EGFR; the disease is cancer.